Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19306461 | 1.00 | CALM1 (0.52) | CALM1POLBTSHRLTA4HL3MBTL1 | |
| SCHEMBL21807128 | 1.00 | CALM1 (0.52) | CALM1POLBTSHRLTA4HL3MBTL1 | |
| Hydrochloric Acid SCHEMBL11638839 | 0.88 | LOXL2 (0.43) | CALM1POLBLTA4HL3MBTL1PLA2G10 | |
| SCHEMBL9566501 | 0.87 | CALM1 (0.61) | CALM1TSHRLTA4HIDH1LMNA | |
| SCHEMBL7752320 | 0.85 | IDH1 (0.42) | CALM1POLBIDH1DPP7PLA2G10 | |
| Hydrochloric Acid SCHEMBL11522917 | 0.83 | IDH1 (0.41) | CALM1POLBIDH1DPP7PLA2G10 | |
| SCHEMBL16322334 | 0.82 | TP53 (0.46) | CALM1TSHRLTA4HLMNA | |
| Diphenylmethane SCHEMBL28085719 | 0.81 | CALM1 (0.80) | CALM1LTA4HIDH1HRH3PLA2G10 | |
| Diphenylmethane SCHEMBL28072604 | 0.81 | CALM1 (0.80) | CALM1LTA4HIDH1HRH3PLA2G10 | |
| SCHEMBL9806319 | 0.81 | CALM1 (0.42) | CALM1POLBTSHRLTA4HL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171436-A1 | TREATMENT OF ANTIFOLATE NEUROTOXICITY | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8101635-B2 | Use of glutamate antagonists which is a NMDA receptor antagonist ( ifenprodil, memantine) to reduce or control retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy ( vision defect ) | ALLERGAN, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080193502-A1 | MEMANTINE INTRAVITREAL IMPLANTS | ALLERGAN, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080193503-A1 | MEMANTINE INTRAVITREAL IMPLANTS | ALLERGAN, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20070148208-A1 | ANTI-EXCITITOXIC SUSTAINED RELEASE INTRACULAR IMPLANTS AND RELATED METHODS | ALLERGAN, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070141117-A1 | ANTI-EXCITITOXIC SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS | ALLERGAN, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7230032-B2 | Calcium blockers to treat proliferative vitreoretinopathy | ALLERGAN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| CN-1950069-A | Anti-excititoxic sustained release intracular implants and related methods | ALLERGAN INC (US) | 2007-04-18 | — | — | CN | disclosed |
| US-20050244478-A1 | Anti-excititoxic sustained release intraocular implants and related methods | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050244473-A1 | Memantine intravitreal implants | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050009884-A1 | Calcium blockers to treat proliferative retinal diseases | ALLERGAN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040266808-A1 | Utilizing N-methyl-D-aspartate (NMDA) receptor antagonist at levels without side effects; uncompetitive open channel blocking | SYNTRIX BIOSYSTEMS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6573280-B2 | Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent | ALLERGAN, INC. | 2003-06-03 | — | — | US | disclosed |
| EP-0797442-B1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRM (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6482854-B1 | Glaucoma treatment | MASSACHUSETTS EYE AND EAR INFIRMARY | 2002-11-19 | — | — | US | disclosed |
| EP-0797442-A4 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRM (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0797442-A1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 1997-10-01 | — | — | EP | disclosed |
| US-5597809-A | METHYL ASPARTATE MEDIATED RETINAL CELL DAMAGE | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 1997-01-28 | — | — | US | disclosed |
| WO-1996000073-A1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 1996-01-04 | — | — | WO | disclosed |
| EP-0338532-A2 | N-alkylamino derivates of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |